Novo Nordisk ($NVO@Denmark) is reducing the supply of starter doses of its obesity drug Wegovy in the US due to surging demand. CFO, Karsten Munk Knudsen, said that halving the supply of starter doses was to ensure continuity of care for existing patients and that the company was ramping up supply, with two contract manufacturers working to boost output and a third expected to come online in H2 2023. Wegovy is one of several drugs tackling rising global obesity rates. The drug has received regulatory approval in several countries, including the UK, and is one of several drugs, alongside Ozempic and Mounjaro, that have been drawing attention amid a growing push to tackle rising global obesity rates.